MedTrace Logo

Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH

NCT06237348 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-04

No results posted yet for this study

Summary

This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and telecare feasibility.

Conditions

  • Non-cystic Fibrosis Bronchiectasis
  • Chronic Mucus Hypersecretion

Interventions

DEVICE

Simeox

Daily airway clearance therapy at home during 2 months

COMBINATION_PRODUCT

Control

Daily airway clearance therapy at home during 2 months

Sponsors & Collaborators

  • Medical University of Lodz

    collaborator OTHER

  • University Hospital in Krakow

    collaborator OTHER

  • Physio-Assist

    lead INDUSTRY

Principal Investigators

  • Wojciech PIOTROWSKI, MD, PhD · Medical University of Lodz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-15
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237348 on ClinicalTrials.gov